Iterative Health specializes in advancing artificial intelligence-based precision medicine in gastroenterology, particularly through clinical trials for inflammatory bowel disease (IBD). The company utilizes machine learning and computer vision to analyze endoscopic videos and supplementary patient data, enabling healthcare professionals to make more accurate assessments and improve patient care. By establishing more meaningful endpoints, Iterative Health aims to enhance predictive capabilities for treatment responses and patient outcomes. Committed to equitable healthcare, the company seeks to create an inclusive environment that reflects the diverse patient populations it serves, driving innovation in clinical decision-making and improving overall health outcomes.